{"id":6526,"date":"2025-09-02T23:02:20","date_gmt":"2025-09-02T23:02:20","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/09\/02\/biotech-news-corsera-ionis-replimune-cytokinetics\/"},"modified":"2025-09-02T23:02:20","modified_gmt":"2025-09-02T23:02:20","slug":"biotech-news-corsera-ionis-replimune-cytokinetics","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/09\/02\/biotech-news-corsera-ionis-replimune-cytokinetics\/","title":{"rendered":"STAT+: Trump pressures drugmakers amid CDC turmoil"},"content":{"rendered":"<p>    STAT+: Trump pressures drugmakers amid CDC turmoil<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p><em>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/em><\/p>\n<p>Welcome back from the holiday weekend. Today we have some candor in ALL CAPS from Trump on Covid vaccines, glowy data from Ionis that could lead to an expanded approval for olezarsen, and more.<\/p>\n<h2 class=\"wp-block-heading\" id=\"h-the-need-to-know-this-morning\">The need-to-know this morning<\/h2>\n<ul class=\"wp-block-list\">\n<li>\n<strong>United Therapeutics<\/strong> reported <a href=\"https:\/\/ir.unither.com\/press-releases\/2025\/09-02-2025-120037033\" rel=\"noopener\">positive results<\/a> from a Phase 3 study of its inhaled medicine Tyvaso in patients with idiopathic pulmonary fibrosis.<\/li>\n<li>\n<strong>Replimune Group<\/strong> said a <a href=\"https:\/\/ir.replimune.com\/news-releases\/news-release-details\/replimune-announces-type-meeting-scheduled-fda\" rel=\"noopener\">meeting with FDA officials<\/a> has been scheduled to discuss the recent rejection of its treatment for advanced melanoma.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\" id=\"h-veteran-drugmakers-launch-corsera-to-fight-heart-disease\">Veteran drugmakers launch Corsera to fight heart disease<\/h2>\n<p>Biotech veterans John Maraganore, previously the CEO\u00a0of Alnylam, and Clive Meanwell, previously the CEO of The Medicines Company, have teamed up before to develop\u00a0drugs. Now they\u2019re doing so again to launch Corsera Health, a startup aiming to prevent cardiovascular disease, STAT\u2019s Allison DeAngelis writes. The company is developing an AI risk-prediction tool and a dual-target RNAi therapy against PCSK9 and angiotensinogen<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/09\/02\/biotech-news-corsera-ionis-replimune-cytokinetics\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Meghana Keshavan<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/09\/02\/biotech-news-corsera-ionis-replimune-cytokinetics\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: Trump pressures drugmakers amid CDC turmoil Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter in your inbox. Welcome back from the holiday weekend. Today we have some candor in ALL CAPS from Trump on Covid vaccines, glowy data from Ionis that could lead to [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,58,2208,2209,2176,858,2207],"tags":[2150],"class_list":["post-6526","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-business","category-drug-development","category-drug-prices","category-pharma","category-research","category-the-readout","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6526"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=6526"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/6526\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=6526"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=6526"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=6526"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}